Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

20.62 -3.06 (-12.92%)
Streaming Delayed Price Updated: 2:41 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biohaven Ltd. Common Shares

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
From Pomerantz LLP
Via GlobeNewswire
NYSE:BHVN Investor Alert: Investigation Concerning Possible Securities Laws Violations by Biohaven Ltd.
San Diego, CA -- (SBWIRE) -- 08/23/2023 -- Biohaven Ltd. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug. 
Via MarketBeat
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 3/8
Via Investor Brand Network
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 3/4
Via Investor Brand Network
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is a Stock Spotlight on 1/5
Via Investor Brand Network
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Sets New 52-Week High in Monday Session
Via Investor Brand Network
Biohaven Ltd. (NYSE: BHVN) Records 52-Week High Thursday Morning
Via Investor Brand Network
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Rise Above Previous 52-Week High
Via Investor Brand Network
Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Exceed 52-Week High
Via Investor Brand Network
Watch for Continued Gains in Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Via Investor Brand Network
Is Viatris Inc. a Contrarian Dividend Option for Your Portfolio?
Does kicking against market trends make you even more excited about investing? If so, you may want to consider drugmaker Viatris Inc. (NASDAQ: VTRS), which produces products that treat diabetes,... 
Via MarketBeat
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
From Global Coalition for Adaptive Research
Via Business Wire
BIOHAVEN INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN
From Kahn Swick & Foti, LLC
Via Business Wire
BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
Pfizer to Acquire Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
From Pfizer Inc.
Via Business Wire
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
Via AB Newswire
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
From Biohaven Pharmaceuticals
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.